ADHD shows up everywhere on the USMLE: kid can’t sit still in clinic, teen’s grades are tanking, adult can’t keep a job, and the vignette quietly tests diagnostic criteria, comorbidities, and first-line meds (plus their side effects). This post is your Step-focused “one stop shop” for definition → neurobiology → diagnosis → treatment → classic associations, with quick First Aid-style cross-references you can mentally anchor to.
What ADHD is (Step definition)
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.
Key Step language:
- Symptoms are present in ≥ 2 settings (e.g., home and school/work)
- Onset before age 12
- Duration ≥ 6 months
- Causes impairment (academic, occupational, social)
- Not better explained by another disorder (anxiety, depression, substance intoxication, etc.)
First Aid cross-ref: Psychiatry → Neurodevelopmental disorders (ADHD); also tie-ins under Stimulants (MOA/SE) and Substance use disorders.
Pathophysiology (what’s going on in the brain)
Think: frontostriatal circuitry and catecholamines.
Neurobiology (high-yield)
- Dysregulation of dopamine (DA) and norepinephrine (NE) signaling, especially in:
- Prefrontal cortex (executive function, attention, inhibition)
- Basal ganglia/striatal circuits (motor activity, reward processing)
- Strong heritability (ADHD runs in families)
Why stimulants help
Stimulants increase catecholamine signaling, improving:
- signal-to-noise in the prefrontal cortex
- top-down control of attention and impulses
Step-friendly mechanism summary:
- Methylphenidate: blocks DA and NE reuptake
- Amphetamines: increase release of DA and NE (and inhibit reuptake)
First Aid cross-ref: Pharmacology → CNS stimulants (methylphenidate, amphetamines).
Clinical presentation (how vignettes give it away)
ADHD symptoms fall into two clusters:
1) Inattention
Common vignette clues:
- careless mistakes, “doesn’t seem to listen”
- poor follow-through, disorganized
- avoids sustained mental effort (homework)
- loses things, easily distracted, forgetful
2) Hyperactivity/impulsivity
Common vignette clues:
- fidgeting, leaving seat, “driven by a motor”
- talks excessively, blurts out answers
- difficulty waiting turn, interrupts others
Presentations by age (classic Step nuance)
- Children: disruptive classroom behavior, incomplete assignments, “always in trouble”
- Adolescents: academic decline, risky behavior, driving accidents
- Adults: poor time management, job instability, relationship stress; hyperactivity often becomes inner restlessness
Diagnosis (DSM-5 essentials you must know)
Core DSM-5 criteria (board-relevant)
- ≥ 6 symptoms of inattention and/or hyperactivity-impulsivity
- Age < 17: ≥ 6
- Age ≥ 17: ≥ 5
- Present ≥ 6 months
- Several symptoms before age 12
- Present in ≥ 2 settings
- Clear impairment
- Not better explained by another disorder
ADHD subtypes (know the labels)
| Presentation | What it means |
|---|---|
| Predominantly inattentive | Inattention criteria met; hyperactivity/impulsivity not met |
| Predominantly hyperactive/impulsive | Hyperactivity/impulsivity criteria met; inattention not met |
| Combined presentation | Both criteria met |
The “don’t miss” workup points
ADHD is clinical, but Step questions often test what you should screen/consider:
- Sleep problems (insufficient sleep, OSA)
- Learning disorders
- Anxiety/depression
- Substance use (especially in adolescents/young adults)
- Medication causes (e.g., too much caffeine, decongestants)
- Vision/hearing issues in children if academic issues are vague
High-yield differentials (common Step traps)
| Looks like ADHD, but… | Clue | Diagnosis to consider |
|---|---|---|
| Child can’t focus only at school | Not in multiple settings | Learning disorder, classroom mismatch |
| Restless + worried + somatic symptoms | Rumination, fear-based | Generalized anxiety disorder |
| Distractible + decreased need for sleep, grandiosity | Episodic | Bipolar disorder (mania/hypomania) |
| Inattention after trauma | Re-experiencing, hypervigilance | PTSD |
| Inattention with persistent low mood | Neurovegetative symptoms | Major depressive disorder |
| Teen “spacing out” | Brief spells, automatisms | Absence seizures/focal seizures (rare but testable) |
Comorbidities & associations (HY for Step 1/2)
ADHD travels with friends. These are high-yield pairings:
Common comorbidities
- Oppositional defiant disorder (ODD) (arguing, defiance, vindictive; no serious rights violations)
- Conduct disorder (aggression, property destruction, deceit/theft, serious rule violations)
- Learning disorders
- Anxiety and depression
- Substance use disorders (especially later; also relevant due to stimulant diversion/misuse)
Developmental associations
- Tic disorders and Tourette’s can co-occur (important when choosing meds and managing side effects)
Step pearl: Conduct disorder + ADHD is a classic “risk for future antisocial outcomes” stem, but don’t diagnose antisocial personality disorder until age ≥ 18 (and there must be conduct disorder before age 15).
Treatment (what the test expects)
First-line: stimulants (most effective)
Methylphenidate or amphetamines are first-line for most patients.
Key adverse effects (USMLE loves these):
- Decreased appetite → weight loss
- Insomnia
- Increased HR/BP
- Anxiety/irritability
- Growth suppression (monitor height/weight in kids; effect is usually modest)
- Risk of misuse/diversion (especially adolescents/college)
Monitoring basics
- Baseline and follow-up: BP/HR, weight, sleep, mood
- Consider cardiac history; if significant personal/family cardiac disease, evaluate appropriately before starting stimulants
First Aid cross-ref: Pharm → stimulants; Psych → ADHD management.
Nonstimulants (when/why to use)
Use when:
- stimulant side effects are intolerable
- concern for misuse/diversion
- comorbidities suggest an alternative
High-yield nonstimulants:
- Atomoxetine (selective NE reuptake inhibitor)
- Great Step clue: nonstimulant for ADHD
- Takes longer than stimulants to work
- Side effects: GI upset, sleep changes; can increase BP/HR
- Alpha-2 agonists: guanfacine, clonidine
- Helpful for hyperactivity/impulsivity and sometimes tics
- Side effects: sedation, hypotension
Behavioral and school-based interventions (Step 2 vibe)
- Parent training and behavioral therapy (especially in younger children)
- Classroom accommodations (structured routines, seating, extra time)
Step pearl: Combined approach (meds + behavioral strategies) improves function more than either alone in many patients.
ADHD + Substance Use (your “Substance Use & Development” tie-in)
This is a frequent USMLE angle because it tests both developmental risk and medication safety.
The relationship in vignettes
- ADHD is associated with increased risk of substance use disorders (SUD), particularly when untreated and with comorbid conduct problems.
- Stimulants are controlled substances and can be misused/diverted—watch for:
- college student requesting early refills
- “lost prescription”
- inconsistent follow-up
Practical testable management points
- If SUD risk is high or diversion is suspected:
- consider atomoxetine or guanfacine/clonidine
- use closer monitoring strategies (frequent visits, limited quantities)
- Treat comorbid SUD appropriately; don’t ignore it because “it’s just ADHD.”
Classic vignette patterns (quick recognition)
Pediatric classic
8-year-old boy, “always out of seat,” blurts answers, incomplete homework, teacher complaints; parents report same at home. Symptoms since early childhood.
Adolescent classic
15-year-old with worsening grades, impulsive decisions, minor accidents, trouble finishing tasks; symptoms present since elementary school.
Adult classic
28-year-old with chronic lateness, missed deadlines, job hopping, messy finances; recalls childhood “daydreaming” and school difficulties.
HY “must memorize” checklist
- Before age 12, ≥ 6 months, ≥ 2 settings, impairment
- Stimulants first-line (methylphenidate/amphetamines)
- Stimulant side effects: decreased appetite, insomnia, ↑BP/HR, possible growth suppression
- Nonstimulants: atomoxetine, guanfacine, clonidine
- Common comorbidities: ODD, conduct disorder, learning disorders, anxiety/depression
- Strong association with substance use risk and med diversion concerns
First Aid-style cross-references (mental map)
While First Aid organization can vary by edition, ADHD content typically cross-links to:
- Psychiatry → Neurodevelopmental disorders → ADHD
- criteria, presentation, comorbidities
- Pharmacology → CNS stimulants
- methylphenidate/amphetamines MOA and adverse effects
- Psychiatry/Behavioral science → Substance use disorders
- risk, misuse/diversion framing
- Psychiatry → Disruptive behavior disorders
- ODD vs conduct disorder vs ADHD